GLP-1 statistics & facts (2026)
The key numbers on GLP-1 cost, coverage, and clinical outcomes — every figure with a dated, linked source. Free to cite (attribute to GLP1Zoom with a link).
The headline numbers
Injectable Wegovy's list price is near $1,349/mo before insurance or discounts, though manufacturer cash self-pay (NovoCare) runs far less — about $199/mo introductory and ~$349/mo for maintenance doses; the oral Wegovy pill starts at $149/mo self-pay and brand Zepbound runs $299–$449/mo via LillyDirect. From July 1, 2026 eligible Medicare Part D members can pay about $50/mo. At their highest obesity-trial doses, semaglutide 2.4 mg (Wegovy) cut weight ~14.9% (STEP 1) and tirzepatide 15 mg (Zepbound) ~20.9% (SURMOUNT-1); individual results vary.
Cost
$299–$449/mo
LillyDirect self-pay price for brand Zepbound single-dose vials, by dose.
Eli Lilly · 2026
$149/mo
self-pay introductory price of the oral Wegovy pill (semaglutide 25 mg).
Novo Nordisk (Wegovy.com) · 2026
Insurance & coverage
Clinical outcomes
~20% fewer
major cardiovascular events on semaglutide 2.4 mg in adults with CVD + obesity, no diabetes (SELECT trial).
NEJM · 2023
Prevalence
~40%
of U.S. adults have obesity — the population GLP-1 weight-management drugs target.
CDC (NHANES) · 2023
Regulation
Cite this page
GLP1Zoom, “GLP-1 Statistics & Facts (2026)”. https://glp1zoom.com/glp1-statistics. Figures are drawn from the linked primary sources; see our sourcing standards. Educational only, not medical advice.
Further reading (authoritative sources)
- Prescription medications to treat overweight & obesity — NIH — NIDDKGovernment overview of approved weight-management drugs.
- GLP-1 agonists — overview & how they work — NIH — MedlinePlus
- FDA's concerns with unapproved GLP-1 drugs used for weight loss — U.S. FDA
- Medicaid coverage of and spending on GLP-1s — KFFState-by-state coverage data (2026).